Background: Due to their excellent biocompatibility and biodegradability, poly-epsiloncaprolactone
and its derivative copolymers have been extensively studied as drug carriers in pharmaceutical
and medical fields, especially for controlled release of anti-tumor drugs. Poly-epsiloncaprolactone
based drug delivery systems lead to major advantages including uniform drug distribution,
long term of degradation and drug release process, non-toxic in nature and cyto-compatible
with body tissues. Approved by US Food and Drug Administration, poly-epsilon-caprolactone provides
a promising platform for design and fabrication of anti-tumor drug delivery systems with controllable
drug release behaviors.
Methods: This mini-review focused on the recent progress in application of poly-epsiloncaprolactone
based materials for controlled release of cancer therapy drugs. A careful search was
performed on web of science, mainly focused on the related papers published from 2013 to 2016.
Conclusion: Recent advances in applying poly-epsilon-caprolactone for controlled delivery and targeting
release of chemical anti-tumor drugs were summarized in this mini-review. Benefited from
the efforts of scientists all over the world, various chemotherapeutic drug delivery systems based on
different formulations of poly-epsilon-caprolactone related materials have been evaluated. It has
been widely recognized that the introduction of of poly-epsilon-caprolactone components into drug
delivery systems would increase drug loading capacity, decrease leakage, prolong releasing period
and result in controllable releasing rate. Especially with the development of environment-responsive
delivery systems (pH-, thermo-, magnetic field- and light-responsive drug carriers), enhanced tumor
cell targeting potential, as well as decreased systemic toxicity would be realized.